Acadia Pharmaceuticals (ACAD) Cash & Equivalents Growth (3y) (2013 - 2026)

Acadia Pharmaceuticals (ACAD) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -8.88%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 47.78%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Acadia Pharmaceuticals 4.35 Bn 3.50 Bn 243.27 Mn -1.01%

Historic Data

Download Data
DateValue
Mar 31, 2026 -1.01%
Dec 31, 2025 15.66%
Sep 30, 2025 18.55%
Jun 30, 2025 21.96%
Mar 31, 2025 2.04%
Dec 31, 2024 29.42%
Sep 30, 2024 17.91%
Jun 30, 2024 -12.78%
Mar 31, 2024 -12.39%
Dec 31, 2023 -16.67%
Sep 30, 2023 -39.90%
Jun 30, 2023 -29.68%
Mar 31, 2023 18.90%
Dec 31, 2022 -15.40%
Sep 30, 2022 -26.22%
Jun 30, 2022 23.39%
Mar 31, 2022 28.07%
Dec 31, 2021 3.04%
Sep 30, 2021 13.99%
Jun 30, 2021 53.24%